GENOVATE BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.05 TWD | -0.21% |
|
+1.05% | -9.59% |
| Sales 2022 | 439M 13.47M 1.12B | Sales 2023 | 529M 16.23M 1.35B | Capitalization | 2.91B 89.33M 7.45B |
|---|---|---|---|---|---|
| Net income 2022 | -12M -368K -30.74M | Net income 2023 | 29M 890K 74.29M | EV / Sales 2022 | 6.86 x |
| Net cash position 2022 | 495M 15.21M 1.27B | Net cash position 2023 | 539M 16.54M 1.38B | EV / Sales 2023 | 4.49 x |
| P/E ratio 2022 |
-285
x | P/E ratio 2023 |
99.2
x | Employees | 199 |
| Yield 2022 |
0.54% | Yield 2023 |
0.56% | Free-Float | 69.6% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.21% | ||
| 1 week | +1.05% | ||
| Current month | -3.80% | ||
| 1 month | -3.99% | ||
| 3 months | -5.50% | ||
| 6 months | -9.42% | ||
| Current year | -9.59% |
1 week
24.00
24.40
1 month
23.6025.40
Current year
23.6027.00
1 year
23.6031.95
3 years
20.8541.85
5 years
16.1551.42
10 years
16.1572.87
| Managers | Title | Age | Since |
|---|---|---|---|
Chia Chen Chu
CEO | Chief Executive Officer | - | 23/17/23 |
Hui ling Lin
DFI | Director of Finance/CFO | - | 01/09/01 |
Cheng Chen
CHM | Chairman | 69 | 14/93/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheng Chen
CHM | Chairman | 69 | 14/93/14 |
Howard Lee
BRD | Director/Board Member | 62 | 10/14/10 |
Ko Yi Liu
BRD | Director/Board Member | 58 | 01/17/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 24.05 | -0.21% | 152,244 |
| 25/24/25 | 24.1 | -0.82% | 129,821 |
| 24/24/24 | 24.3 | +0.21% | 208,627 |
| 23/24/23 | 24.25 | +1.46% | 202,714 |
| 22/24/22 | 23.9 | +0.42% | 113,088 |
End-of-day quote Taipei Exchange, April 26, 2024
More quotes
Genovate Biotechnology Co., LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates. The Company's products include nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs, cardiovascular system drugs, acne drugs, antineoplastic drugs and anti-diabetic drugs, as well as healthcare food and cosmetics. The Company is also engaged in the provision of clinical experimental testing services and technology export services. The Company distributes its products mainly within domestic market.
Sector
Pharmaceuticals
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -9.59% | 80.64M | |
| +25.83% | 661B | |
| +27.04% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.66% | 231B | |
| +5.03% | 200B | |
| -9.16% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4130 Stock
